171 related articles for article (PubMed ID: 38622256)
1. Exclusive expression of KANK4 promotes myofibroblast mobility in keloid tissues.
Oishi M; Shinjo K; Takanari K; Muraoka A; Suzuki MM; Kanbe M; Higuchi S; Ebisawa K; Hashikawa K; Kamei Y; Kondo Y
Sci Rep; 2024 Apr; 14(1):8725. PubMed ID: 38622256
[TBL] [Abstract][Full Text] [Related]
2. Hypertrophic and keloid scars fail to progress from the CD34
Limandjaja GC; Belien JM; Scheper RJ; Niessen FB; Gibbs S
Br J Dermatol; 2020 Apr; 182(4):974-986. PubMed ID: 31206605
[TBL] [Abstract][Full Text] [Related]
3. Endothelial cell-derived endothelin-1 is involved in abnormal scar formation by dermal fibroblasts through RhoA/Rho-kinase pathway.
Kiya K; Kubo T; Kawai K; Matsuzaki S; Maeda D; Fujiwara T; Nishibayashi A; Kanazawa S; Yano K; Amano G; Katayama T; Hosokawa K
Exp Dermatol; 2017 Aug; 26(8):705-712. PubMed ID: 27892645
[TBL] [Abstract][Full Text] [Related]
4. Keloid tissue analysis discredits a role for myofibroblasts in disease pathogenesis.
Bell RE; Shaw TJ
Wound Repair Regen; 2021 Jul; 29(4):637-641. PubMed ID: 33961308
[TBL] [Abstract][Full Text] [Related]
5. The Role of Hippo Signaling Pathway and ILK in the Pathophysiology of Human Hypertrophic Scars and Keloids: An Immunohistochemical Investigation.
Petrou IG; Nikou S; Madduri S; Nifora M; Bravou V; Kalbermatten DF
Cells; 2022 Oct; 11(21):. PubMed ID: 36359821
[TBL] [Abstract][Full Text] [Related]
6. Myofibroblasts Are Not Characteristic Features of Keloid Lesions.
Hahn JM; McFarland KL; Combs KA; Powell HM; Supp DM
Plast Reconstr Surg Glob Open; 2022 Nov; 10(11):e4680. PubMed ID: 36448015
[TBL] [Abstract][Full Text] [Related]
7. Wnt Signaling Pathway Proteins in Scar, Hypertrophic Scar, and Keloid: Evidence for a Continuum?
Chaudet KM; Goyal A; Veprauskas KR; Nazarian RM
Am J Dermatopathol; 2020 Nov; 42(11):842-847. PubMed ID: 32310858
[TBL] [Abstract][Full Text] [Related]
8. Differential apoptosis markers in human keloids and hypertrophic scars fibroblasts.
De Felice B; Garbi C; Santoriello M; Santillo A; Wilson RR
Mol Cell Biochem; 2009 Jul; 327(1-2):191-201. PubMed ID: 19224335
[TBL] [Abstract][Full Text] [Related]
9. Characterization of In Vitro Reconstructed Human Normotrophic, Hypertrophic, and Keloid Scar Models.
Limandjaja GC; van den Broek LJ; Breetveld M; Waaijman T; Monstrey S; de Boer EM; Scheper RJ; Niessen FB; Gibbs S
Tissue Eng Part C Methods; 2018 Apr; 24(4):242-253. PubMed ID: 29490604
[TBL] [Abstract][Full Text] [Related]
10. Periostin induces fibroblast proliferation and myofibroblast persistence in hypertrophic scarring.
Crawford J; Nygard K; Gan BS; O'Gorman DB
Exp Dermatol; 2015 Feb; 24(2):120-6. PubMed ID: 25421393
[TBL] [Abstract][Full Text] [Related]
11. Keloids are transcriptionally distinct from normal and hypertrophic scars.
Walter AS; Stocks M; Akova E; Gauglitz G; Hartmann D; Aszodi A; Böcker W; Saller MM; Volkmer E
Eur J Dermatol; 2023 Dec; 33(6):604-611. PubMed ID: 38465540
[TBL] [Abstract][Full Text] [Related]
12. Analysis of protease-activated receptor-1 and -2 in human scar formation.
Materazzi S; Pellerito S; Di Serio C; Paglierani M; Naldini A; Ardinghi C; Carraro F; Geppetti P; Cirino G; Santucci M; Tarantini F; Massi D
J Pathol; 2007 Aug; 212(4):440-9. PubMed ID: 17597495
[TBL] [Abstract][Full Text] [Related]
13. Keloid and Hypertrophic Scars Are the Result of Chronic Inflammation in the Reticular Dermis.
Ogawa R
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28287424
[TBL] [Abstract][Full Text] [Related]
14. mTOR as a potential therapeutic target for treatment of keloids and excessive scars.
Ong CT; Khoo YT; Mukhopadhyay A; Do DV; Lim IJ; Aalami O; Phan TT
Exp Dermatol; 2007 May; 16(5):394-404. PubMed ID: 17437482
[TBL] [Abstract][Full Text] [Related]
15. Nonmuscle Myosin II Activation Regulates Cell Proliferation, Cell Contraction, and Myofibroblast Differentiation in Keloid-Derived Fibroblasts.
Lu YY; Fang CC; Hong CH; Wu CH; Lin YH; Chang KL; Lee CH
Adv Wound Care (New Rochelle); 2020 Sep; 9(9):491-501. PubMed ID: 32941122
[No Abstract] [Full Text] [Related]
16. [The role of myofibroblast in the development of pathological scar].
Liu Y; Cen Y; Ying T; Xu X
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2005 Jan; 19(1):39-41. PubMed ID: 15704840
[TBL] [Abstract][Full Text] [Related]
17. Vascularization pattern in hypertrophic scars and keloids: a stereological analysis.
Amadeu T; Braune A; Mandarim-de-Lacerda C; Porto LC; Desmoulière A; Costa A
Pathol Res Pract; 2003; 199(7):469-73. PubMed ID: 14521263
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical Evaluation of Leptin Expression in Wound Healing: A Clue to Exuberant Scar Formation.
Seleit I; Bakry OA; Samaka RM; Tawfik AS
Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):296-306. PubMed ID: 26258753
[TBL] [Abstract][Full Text] [Related]
19. Recent Understandings of Biology, Prophylaxis and Treatment Strategies for Hypertrophic Scars and Keloids.
Lee HJ; Jang YJ
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29498630
[TBL] [Abstract][Full Text] [Related]
20. Hypertrophic scars and keloids: Overview of the evidence and practical guide for differentiating between these abnormal scars.
Limandjaja GC; Niessen FB; Scheper RJ; Gibbs S
Exp Dermatol; 2021 Jan; 30(1):146-161. PubMed ID: 32479693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
